Lipid-lowering Therapies for Familial Hypercholesterolemia
Cardiology
Curriculum:
Achieving LDL Goals in Patients with Hypercholesterolemia
Achieving LDL Goals in Patients with Hypercholesterolemia
Credits:
0.75 AMA PRA Category 1 Credit(s) ™
0.75 AMA PRA Category 1 Credit(s) ™
Launch Date:
August 04, 2016
August 04, 2016
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Primary Care Physicians; Nurse Practitioners; Physician Assistants
Relevant Terms:
Lipid management; cardiovascular disease; athersclerosis; familial hypercholesterolemia; dyslipidemia
P. Barton Duell, MD, FNLA, FAHA
P. Barton Duell, MD, FNLA, FAHA
Director, Lipid Disorders Clinic and LDL Apheresis
Director, Lipid-Atherosclerosis Laboratory
Knight Cardiovascular Institute
Division of Endocrinology, Diabetes, and Clinical Nutrition
Oregon Health and Science University
Portland, Oregon
Bio
Dr. Duell's special areas of interest include lipoprotein pathophysiology and genetics, homocysteine metabolism, prevention of atherosclerosis, diabetes, endocrinology and management of obesity. He currently serves as the director of OHSU`s Lipid Disorders Clinic, Director of the LDL-Atherosclerosis Laboratory, and Director of the LDL Apheresis Unit. He received his medical degree from OHSU in 1983, and completed his Medicine residency at OHSU and the University of Chicago. He completed his Metabolism, Endocrinology and Nutrition fellowship at the University of Washington in Seattle with a focus on lipoprotein metabolism and diabetes. Dr. Duell is board certified in Internal Medicine (1986), and Endocrinology and Metabolism (1989).
Ty J. Gluckman, MD, FACC, FAHA
Ty J. Gluckman, MD, FACC, FAHA
Medical Director, Clinical Excellence
Providence Heart and Vascular Institute, Oregon Region
Portland, Oregon
Bio
Dr. Ty J. Gluckman is Director of Clinical Excellence at the Heart and Vascular Institute of Providence St. Vincent Medical Center in Portland, Oregon and an adjunct member of the The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, Maryland. Dr. Gluckman graduated summa cum laude with highest honors from Brandeis University. He received his medical degree from Northwestern University Medical School and did his internal medicine training at McGaw Medical Center of Northwestern University, where he remained for additional years as chief resident and an Instructor in Medicine. He completed his cardiology fellowship training at the Johns Hopkins Hospital and served as chief fellow during his final year there. His principal clinical and research interests include the management of acute coronary syndromes, the evaluation of premature graft failure after coronary artery bypass graft surgery, and variability in responsiveness to antiplatelet agents. Dr. Gluckman serves as co-editor of the National Preventive Cardiology CME Newsletter Cardiology News and Issues in the New Millennium, which has a circulation of nearly 100,000 physicians and has recent publications in the Archives of Internal Medicine, JAMA, and the Journal of the American College of Cardiology. He is an active councilor and Director of Quality for the State of Oregon Chapter of the American College of Cardiology, a board member of the Portland Metro and SW Washington Chapter of the American Heart Association, and associate editor for clinical documents and practice guidelines for Cardiosource.
Bruce S. Stambler, MD
Bruce S. Stambler, MD
Director of Cardiac Arrhythmia Research and Education
Piedmont Heart Institute
Atlanta, Georgia
Bio
Bruce Stambler, MD, earned his medical degree from Duke University School of Medicine. He completed his internal medicine residency and clinical and research fellowship in cardiology at Beth Israel Hospital, Harvard Medical School in Boston, Massachusetts. He then completed a clinical and research fellowship in cardiac electrophysiology at Massachusetts General Hospital in Boston, Massachusetts.
Prior to joining Piedmont Heart, Dr. Stambler practiced at University Hospitals of Cleveland, where he served as Director of Clinical Electrophysiology and Pacing and Director of the Electrophysiology Fellowship Program. He was a Professor of Medicine at Case Western Reserve University in Cleveland, Ohio. He is board certified in cardiology and cardiac electrophysiology. He was consistently selected as a Best/Top Doctor in America from 2004-2014. A fellow of the American College of Cardiology, American Heart Association and the Heart Rhythm Society, Dr. Stambler is very active in research and education in cardiac electrophysiology. At Piedmont Heart, he serves as Director of Cardiac Arrhythmia Research and Education.
| 1. | Discuss the limitations of currently available lipid-lowering agents and the need for novel treatment options | 2. | Describe the mechanism of action, efficacy and safety of PCSK9 inhibitors and what differentiates them from other forms of lipid-lowering therapy |
| 3. | Review the clinical trial data supporting the use of PCSK9 inhibitors to lower LDL cholesterol and ongoing outcomes trials in at-risk patients with hypercholesterolemia | 4. | Apply current evidence-based therapies to optimize control of LDL-C in patients with hypercholesterolemia |
| 1. | Discuss the limitations of currently available lipid-lowering agents and the need for novel treatment options |
| 2. | Describe the mechanism of action, efficacy and safety of PCSK9 inhibitors and what differentiates them from other forms of lipid-lowering therapy |
| 3. | Review the clinical trial data supporting the use of PCSK9 inhibitors to lower LDL cholesterol and ongoing outcomes trials in at-risk patients with hypercholesterolemia |
| 4. | Apply current evidence-based therapies to optimize control of LDL-C in patients with hypercholesterolemia |
LAUNCH DATE/EXPIRATION DATE
This activity was launched on August 4, 2016 and will expire on August 4, 2017.
TARGET AUDIENCE
This activity has been designed to meet the educational needs of primary care clinicans, NPs, PAs and other health care professionals involved in the care of patients with dyslipidemia.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been designed to meet the educational needs of primary care clinicans, NPs, PAs and other health care professionals involved in the care of patients with dyslipidemia.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO CLAIM CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.75 AMA PRA Category 1 credits™. Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 75% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
LEARNER ASSURANCE STATEMENT
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
| Name of Faculty | Reported Financial Relationship |
| P. Barton Duell, MD, FNLA, FAHA | Dr. Duell has served on a Speakers Bureau for Genzyme and Sanofi. He has also served on Medical Advisory Boards for Genzyme, Sanofi, Akcea Therapeutics, Regeneron Pharmaceuticals, Kaneka Corporation, and Aegerion Pharmaceuticals. Dr. Duell has also performed contracted research for Genzyme, Kaneka Corporation, Regeneron Pharmaceuticals, and Amgen. |
| Ty J. Gluckman, MD, FACC, FAHA | Neither Dr. Gluckman nor his spouse/partner have any relevant financial relationships within the past 12 months with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. |
| Bruce S. Stambler, MD | Neither Dr. Stambler nor his spouse/partner have any relevant financial relationships within the past 12 months with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. |
HORIZON PLANNER DISCLOSURES
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
SUPPORT ACKNOWLEDGEMENT
This educational program is being supported by an independent educational grant from Sanofi U.S. and Regeneron Pharmaceuticals.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
